Wei X, Zhang Z, Chong MKC, Hicks JP, Gong W, Zou G, et al. Evaluation of a package of risk-based pharmaceutical and lifestyle interventions in patients with hypertension and/or diabetes in rural China: a pragmatic cluster randomised controlled trial. PLoS Med. 2021;18: e1003694.

Article  PubMed  PubMed Central  Google Scholar 

Ferrari R, Catapano AL. Residual cardiovascular risk. Eur Heart J Suppl. 2016;18:C1.

Article  PubMed  Google Scholar 

Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL-cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012;14:1–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gomez-Delgado F, Raya-Cruz M, Katsiki N, Delgado-Lista J, Perez-Martinez P. Residual cardiovascular risk: when should we treat it? Eur J Intern Med. 2023;S0953–6205(23):00368.

Google Scholar 

NLRP3 inflammasome and the IL-1 pathway in atherosclerosis [cited 10 Nov 2023]. https://pubmed.ncbi.nlm.nih.gov/29880500/.

Lutgens E, Atzler D, Döring Y, Duchene J, Steffens S, Weber C. Immunotherapy for cardiovascular disease. Eur Heart J. 2019;40:3937–46.

Article  CAS  PubMed  Google Scholar 

Nelson K, Fuster V, Ridker PM. Low-dose colchicine for secondary prevention of coronary artery disease: JACC review topic of the week. J Am Coll Cardiol. 2023;82:648–60.

Article  CAS  PubMed  Google Scholar 

Deftereos SG, Beerkens FJ, Shah B, Giannopoulos G, Vrachatis DA, Giotaki SG, Siasos G, et al. Colchicine in cardiovascular disease: in-depth review. Circulation. 2022;145:61–78.

CAS  PubMed  Google Scholar 

Lamb YN. Inclisiran: first approval. Drugs. 2021;81:389–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol [cited 10 Nov 2023]. https://pubmed.ncbi.nlm.nih.gov/32187462/.

The evolving future of PCSK9 inhibitors [cited 10 Nov 2023]. https://pubmed.ncbi.nlm.nih.gov/30012326/.

Reijnders E, van der Laarse A, Jukema JW, Cobbaert CM. High residual cardiovascular risk after lipid-lowering: prime time for predictive, preventive, personalized, participatory, and psycho-cognitive medicine. Front Cardiovasc Med. 2023;10:1264319.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng M, Fu H-Z, Ho Y-S. Research trends and hotspots related to ammonia oxidation based on bibliometric analysis. Environ Sci Pollut Res Int. 2017;24:20409–21.

Article  CAS  PubMed  Google Scholar 

Hicks D, Wouters P, Waltman L, de Rijcke S, Rafols I. Bibliometrics: The Leiden Manifesto for research metrics. Nature. 2015;520:429–31.

Article  PubMed  Google Scholar 

Ninkov A, Frank JR, Maggio LA. Bibliometrics: methods for studying academic publishing. Perspect Med Educ. 2022;11:173–6.

Article  PubMed  Google Scholar 

Chen C, Song M. Visualizing a field of research: a methodology of systematic scientometric reviews. PLoS ONE. 2019;14:e0223994.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen C. CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci Technol. 2006;57:359–77.

Article  Google Scholar 

van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84:523–38.

Article  PubMed  Google Scholar 

Aria M, Cuccurullo C. bibliometrix: An R-tool for comprehensive science mapping analysis. J Informetr. 2017;11:959–75.

Article  Google Scholar 

Chen C. The centrality of pivotal points in the evolution of scientific networks. In: Proceedings of the 10th international conference on intelligent user interfaces. New York: Association for Computing Machinery; 2005. p. 98–105. https://doi.org/10.1145/1040830.1040859.

Hirsch JE. An index to quantify an individual’s scientific research output. Proc Natl Acad Sci USA. 2005;102:16569–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Egghe L. Theory and practise of the g-index. Scientometrics. 2006;69:131–52.

Article  Google Scholar 

Chen C, Leydesdorff L. Patterns of connections and movements in dual-map overlays: a new method of publication portfolio analysis. J Assoc Inf Sci Technol. 2014;65:334–51.

Article  Google Scholar 

Batista-Canino RM, Santana-Hernández L, Medina-Brito P. A scientometric analysis on entrepreneurial intention literature: Delving deeper into local citation. Heliyon. 2023;9: e13046.

Article  PubMed  PubMed Central  Google Scholar 

AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67.

Article  Google Scholar 

Fruchart J-C, Sacks FM, Hermans MP, Assmann G, Brown WV, Ceska R, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008;5:319–35.

Article  PubMed  Google Scholar 

Fruchart J-C, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;13:26.

Article  PubMed  PubMed Central  Google Scholar 

Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet Lond Engl. 2010;376:333–9.

Article  CAS  Google Scholar 

Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2014;129:635–42.

Article  CAS  PubMed  Google Scholar 

Tsimikas S. A Test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69:692–711.

Article  CAS  PubMed  Google Scholar 

Mora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ, et al. Determinants of residual risk in secondary prevention patients treated with high-versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation. 2012;125:1979–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, et al. Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study. Am Heart J. 2018;206:80–93.

Article  CAS  PubMed  Google Scholar 

Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210:353–61.

Article  CAS  PubMed  Google Scholar 

Small H. Co-citation in the scientific literature: A new measure of the relationship between two documents. J Am Soc Inf Sci. 1973;24:265–9.

Article  Google Scholar 

Lu X, Lu C, Yang Y, Shi X, Wang H, Yang N, et al. Current status and trends in peptide receptor radionuclide therapy in the past 20 years (2000–2019): a bibliometric study. Front Pharmacol. 2021;12: 624534.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qi X, Zhu Z, Wang Y, Wen Z, Jiang Z, Zhang L, et al. Research progress on the relationship between mitochondrial function and heart failure: a bibliometric study from 2002 to 2021. Front Mol Biosci. 2022;9:1036364.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet Lond Engl. 2005;366:1267–78.

Article  CAS  Google Scholar 

Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet Lond Engl. 2010;376:1670–81.

Article  Google Scholar 

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet Lond Engl. 2005;366:1849–61.

Article  CAS  Google Scholar 

ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–74.

Article  Google Scholar 

Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22.

Article  CAS  PubMed  Google Scholar 

Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504.

Article  CAS